Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Glucagon-like peptides 1 and 2 in health and disease: A review|
|Citation:||Peptides, 2013; 44:75-86|
|Publisher:||Elsevier Science Inc|
|Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones, Michael Horowitz|
|Abstract:||The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent.|
|Keywords:||Pancreas; Animals; Humans; Diabetes Mellitus, Type 2; Blood Glucose; Receptors, Glucagon; Gastric Emptying; Postprandial Period; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Clinical Trials as Topic; Incretins|
|Rights:||© 2013 Elsevier Inc. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.